JP2020533380A - 癌の組合せ治療 - Google Patents
癌の組合せ治療 Download PDFInfo
- Publication number
- JP2020533380A JP2020533380A JP2020515138A JP2020515138A JP2020533380A JP 2020533380 A JP2020533380 A JP 2020533380A JP 2020515138 A JP2020515138 A JP 2020515138A JP 2020515138 A JP2020515138 A JP 2020515138A JP 2020533380 A JP2020533380 A JP 2020533380A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- antibody
- icos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 146
- 201000011510 cancer Diseases 0.000 title claims description 113
- 238000011284 combination treatment Methods 0.000 title description 2
- 102000025171 antigen binding proteins Human genes 0.000 claims abstract description 138
- 108091000831 antigen binding proteins Proteins 0.000 claims abstract description 138
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 80
- 238000000034 method Methods 0.000 claims abstract description 63
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 13
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 350
- 238000011282 treatment Methods 0.000 claims description 63
- 239000003814 drug Substances 0.000 claims description 39
- 150000001413 amino acids Chemical class 0.000 claims description 27
- 230000035772 mutation Effects 0.000 claims description 23
- 229960002204 daratumumab Drugs 0.000 claims description 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 14
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000000556 agonist Substances 0.000 claims description 8
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 7
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 6
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 6
- 101710112752 Cytotoxin Proteins 0.000 claims description 5
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 5
- 239000002619 cytotoxin Substances 0.000 claims description 5
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 239000002955 immunomodulating agent Substances 0.000 abstract description 16
- 229940121354 immunomodulator Drugs 0.000 abstract description 16
- 230000002584 immunomodulator Effects 0.000 abstract description 9
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 39
- 241000282414 Homo sapiens Species 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 32
- 230000002519 immonomodulatory effect Effects 0.000 description 27
- 229940124597 therapeutic agent Drugs 0.000 description 25
- 210000001744 T-lymphocyte Anatomy 0.000 description 23
- 230000027455 binding Effects 0.000 description 23
- 239000012636 effector Substances 0.000 description 21
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 18
- 239000008194 pharmaceutical composition Substances 0.000 description 17
- 208000032839 leukemia Diseases 0.000 description 16
- 206010025323 Lymphomas Diseases 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 239000000427 antigen Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 102100034980 ICOS ligand Human genes 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 12
- 108060003951 Immunoglobulin Proteins 0.000 description 12
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 12
- 102000018358 immunoglobulin Human genes 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 108010059074 monomethylauristatin F Proteins 0.000 description 10
- 230000004913 activation Effects 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 230000011664 signaling Effects 0.000 description 9
- 238000011269 treatment regimen Methods 0.000 description 9
- 208000017604 Hodgkin disease Diseases 0.000 description 8
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 8
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 8
- 101001042104 Homo sapiens Inducible T-cell costimulator Proteins 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 7
- 101710093458 ICOS ligand Proteins 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 102000043396 human ICOS Human genes 0.000 description 7
- 230000036210 malignancy Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 6
- 108010087819 Fc receptors Proteins 0.000 description 6
- 102000009109 Fc receptors Human genes 0.000 description 6
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 6
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 6
- 102000023732 binding proteins Human genes 0.000 description 6
- 108091008324 binding proteins Proteins 0.000 description 6
- 201000000050 myeloid neoplasm Diseases 0.000 description 6
- 150000007523 nucleic acids Chemical group 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 208000021937 marginal zone lymphoma Diseases 0.000 description 5
- 108010093470 monomethyl auristatin E Proteins 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 4
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 description 4
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 208000009527 Refractory anemia Diseases 0.000 description 4
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 4
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 description 4
- 201000005787 hematologic cancer Diseases 0.000 description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 102000046935 human TNFRSF17 Human genes 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000000527 lymphocytic effect Effects 0.000 description 4
- 210000003563 lymphoid tissue Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 108010027122 ADP-ribosyl Cyclase 1 Proteins 0.000 description 3
- 102000018667 ADP-ribosyl Cyclase 1 Human genes 0.000 description 3
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 3
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 3
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000000611 antibody drug conjugate Substances 0.000 description 3
- 229940049595 antibody-drug conjugate Drugs 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 102000052645 human CD38 Human genes 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 206010028537 myelofibrosis Diseases 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- -1 BiTE Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 description 2
- 108010073807 IgG Receptors Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 102100021317 Inducible T-cell costimulator Human genes 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000005931 immune cell recruitment Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 208000037244 polycythemia vera Diseases 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 2
- 238000009117 preventive therapy Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000023761 AL amyloidosis Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- OMNVYXHOSHNURL-WPRPVWTQSA-N Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMNVYXHOSHNURL-WPRPVWTQSA-N 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 210000005236 CD8+ effector T cell Anatomy 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 1
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 101150016644 ICOSLG gene Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 206010053574 Immunoblastic lymphoma Diseases 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 description 1
- 108700013161 Inducible T-Cell Co-Stimulator Proteins 0.000 description 1
- 102000053646 Inducible T-Cell Co-Stimulator Human genes 0.000 description 1
- 101710205775 Inducible T-cell costimulator Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000282852 Lama guanicoe Species 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- 206010060880 Monoclonal gammopathy Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241001416184 Orectolobiformes Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 208000021161 Plasma cell disease Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 206010036673 Primary amyloidosis Diseases 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000023549 cell-cell signaling Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002871 immunocytoma Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000329 lymphopenic effect Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000000248 mediastinal malignant lymphoma Diseases 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000007761 synergistic anti-cancer Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
Abstract
Description
本願は、ASCIIフォーマットで電子提出された配列表を含み、引用することによりその全内容が本明細書の一部とされる。2018年9月10日に作成された前記ASCIIコピーはPU66430_WO_SL.txtの名称で21,096バイトのサイズである。
本発明は、対象において癌を治療する方法に関する。特に、本発明は、癌を治療するための抗BCMA抗原結合タンパク質と免疫調節薬の組合せに関する。
多発性骨髄腫(MM)は、不治の悪性腫瘍であり、総ての癌の1%、総ての血液系悪性腫瘍の10%を占める。多発性骨髄腫の治療において、様々な薬物および組合せ治療が評価され、有効であることが判明している(National Comprehensive Cancer Network, 2016; Moreau, San Miguel et al., 2017)。しかしながら、これらの患者の総てではなくともほとんどが必ず再発する(Richardson, Barlogie et al., 2003; Richardson, Barlogie et al., 2006; Jagannath, Barlogie et al., 2008)。
本開示は、対象、例えば、ヒトにおいて癌を治療する方法に関する。特に、本発明は、癌を治療するための、抗体などの抗BCMA抗原結合タンパク質と免疫調節薬の組合せに関する。一実施形態において、癌は、多発性骨髄腫、慢性リンパ球性白血病、および非ホジキンリンパ腫から選択される。
(i)抗BCMA抗原結合タンパク質;
(ii)ICOSに対する作用物質と組み合わせた場合に癌の治療において使用するための説明書
を含んでなる、癌の治療において使用するためのキットも提供される。
(i)抗BCMA抗原結合タンパク質;
(ii)抗CD38抗原結合タンパク質と組み合わせた場合に癌の治療において使用するための説明書
を含んでなる、癌の治療において使用するためのキットも提供される。
本開示は、対象において癌を治療する方法に関する。特に、本発明は、癌を治療するための、抗BCMA抗原結合タンパク質と免疫調節薬の組合せに関する。理論に縛られるものではないが、本明細書に記載される新規な組合せは、重複しない作用機序のために毒性の軽減をもたらすと考えられる。
本明細書に記載される用語「組合せ」は、少なくとも2つの治療薬を指す。本明細書で使用する場合、用語「治療薬」は、組織、系、動物、哺乳動物、ヒト、または他の対象において所望の効果を生じる物質を意味すると理解される。一実施形態において、この組合せは、抗BCMA抗原結合タンパク質、好適には、抗BCMA抗体と少なくとも1つの付加的治療薬である。一実施形態において、この組合せは、抗BCMA抗原結合タンパク質と免疫調節薬である。別の実施形態において、この組合せは、抗BCMA抗原結合タンパク質とICOSに対する作用物質である。さらに別の実施形態において、この組合せは、抗BCMA抗原結合タンパク質と抗CD38抗原結合剤である。本明細書に記載される組合せは、癌の治療に有効である。
本明細書に記載される組合せ中の抗BCMA抗原結合タンパク質は、癌の治療または予防に有用である。本明細書に開示される抗BCMA抗原結合タンパク質はいずれも、癌を治療するために、免疫調節薬と組み合わせて使用され得る。本明細書に記載される抗BCMA抗原結合タンパク質は、例えば、GenBank受託番号Q02223.2のアミノ酸配列、またはそれと少なくとも90パーセントの相同性または少なくとも90パーセントの同一性を有するヒトBCMAをコードする遺伝子を含有するヒトBCMAを含む、ヒトBCMAと結合し得る。
ABP−((リンカー)n−Ctx)m
を有する免疫複合体であり、ここで、
ABPは、抗原結合タンパク質であり、
リンカーは、不在であるか、または任意の切断可能または非切断可能リンカーであり、
Ctxは、本明細書に記載される任意の細胞傷害性薬剤であり、
nは、0、1、2、または3であり、かつ
mは、1、2、3、4、5、6、7、8、9または10である。
用語「免疫調節薬」は、本明細書で使用する場合、免疫応答を誘導、増強、または抑制する薬剤を指す。免疫調節薬は、免疫応答を惹起もしくは増幅するように設計することができ(活性化免疫調節薬)、または免疫応答を低減もしくは抑制するように設計することもできる(抑制免疫調節薬)。免疫調節薬の例としては、限定されるものではないが、ICOSに対する作用物質および抗CD38抗原結合タンパク質が挙げられる。
一実施形態において、免疫調節薬は、ICOSに対する作用物質である。本明細書で使用する場合、「ICOS」は、いずれの誘導性T細胞補助刺激因子タンパク質も意味する。ICOS(Inducible T-cell COStimulator)の別称としては、AILIM;CD278;CVID1、JTT−1またはJTT−2、MGC39850、または8F4が含まれる。ICOSは、活性化されたT細胞で発現されるCD28スーパーファミリー補助刺激分子である。この遺伝子によりコードされるタンパク質は、CD28およびCTLA−4細胞表面受容体ファミリーに属す。このタンパク質はホモ二量体を形成し、細胞間シグナル伝達、免疫応答、および細胞増殖の調節に有用な役割を果たす。ヒトICOS(アイソフォーム2)(受託番号:UniProtKB−Q9Y6W8−2)のアミノ酸配列は、配列番号11で表される。ヒトICOS(アイソフォーム1)(受託番号:UniProtKB−Q9Y6W8−1)のアミノ酸配列は、配列番号12で表される。
一実施形態において、免疫調節薬は、抗CD38抗原結合タンパク質である。本明細書に記載される組合せ中の抗CD38抗原結合タンパク質は、癌の治療または予防に有用である。本明細書に記載される抗CD38抗原結合タンパク質は、ヒトCD38、例えば、GenBank受託番号D84284.2のアミノ酸配列を含有するヒトCD38、またはそれと少なくとも90パーセントの相同性または少なくとも90パーセントの同一性を有するヒトCD38をコードする遺伝子と結合し得る。
本明細書には、対象における癌を本明細書に記載される組合せで治療するための方法が記載される。本明細書で使用する場合、用語「癌」、および「腫瘍」は、単数形または複数形のいずれかで互換的に使用され、細胞を宿主生物に病的とする悪性化を受けた細胞を指す。原発性癌細胞は、十分に確立された技術、特に組織学的検査によって非癌細胞から容易に識別することができる。癌細胞の定義は、本明細書で使用する場合、原発性癌細胞だけでなく、癌細胞原型に由来するいずれの細胞も含む。これには転移した癌細胞、ならびに癌細胞に由来するin vitro培養物および細胞株が含まれる。固形腫瘍として通常顕在化する癌の一種に言及する場合、「臨床的に検出可能な」腫瘍は、例えば、身体検査でのコンピューター断層撮影(CT)スキャン、磁気共鳴画像法(MRI)、X線、超音波もしくは触診などの手法によって腫瘍塊に基づいて検出可能なもの、および/または患者から取得可能なサンプルにおける1以上の癌特異的抗原の発現のために検出可能なものである。腫瘍は、「液性腫瘍」と呼ぶことができる、造血系(または血液系または血液学的または血液関連)癌、例えば、血液細胞または免疫細胞に由来する癌であり得る。血液系腫瘍に基づく病態の具体例としては、慢性骨髄球性白血病、急性骨髄球性白血病、慢性リンパ球性白血病および急性リンパ球性白血病などの白血病;多発性骨髄腫、MGUSおよびワルデンストロームマクログロブリン血症などの形質細胞悪性腫瘍;非ホジキンリンパ腫、ホジキンリンパ腫などのリンパ腫などが挙げられる。
抗BCMA抗原結合タンパク質および免疫調節薬の適当な治療計画は当業者により容易に決定される。
いくつかの側面において、本開示は、
(i)抗BCMA抗原結合タンパク質;
(ii)ICOSに対する作用物質;および
(iii)癌の治療において使用するための説明書
を含んでなる、癌の治療において使用するためのキットを提供する。
(i)抗BCMA抗原結合タンパク質;
(ii)抗CD38抗原結合タンパク質;および
(iii)癌の治療において使用するための説明書
を含んでなる、癌の治療において使用するためのキットを提供する。
(i)抗BCMA抗原結合タンパク質;
(ii)ICOSに対する作用物質と組み合わせた場合に癌の治療において使用するための説明書
を含んでなる、癌の治療において使用するためのキットを提供する。
(i)抗BCMA抗原結合タンパク質;
(ii)抗CD38抗原結合タンパク質と組み合わせた場合に癌の治療において使用するための説明書
を含んでなる、癌の治療において使用するためのキットを提供する。
配列番号1:抗BCMA抗体CDRH1
1.1 動物
Charles Riverからの雌C57BL/6マウスを本試験で使用した。マウスは、完全に承認されたAAALAC施設で、USDA実験動物福祉法に従った、実験動物の管理と使用に関するNIHガイドライン(NIH Guide for Care and Use of Laboratory Animals)に概説された条件下で飼育した。
ヒトBCMAを過剰発現するEL4マウスリンパ腫細胞(EL4−hBCMA)を作出した。EL4−hBCMAを液体窒素保存から取り出し、解凍し、無菌培地(10%ウシ胎仔血清(FBS)を含有するDMEM)を含有する培養フラスコに移した。これらの細胞を接種前に最低3回継代培養した。BCMA発現細胞を選択するために、G418(培地中終濃度0.2mg/ml)を初代培養およびその後の継代培養毎に添加した。腫瘍細胞は、加湿インキュベーターにて5%CO2中、37℃で、組織培養フラスコ内で維持した。接種直前に、細胞を氷冷DMEMで3回洗浄し、冷DMEM中1.0×106細胞/mlの濃度とした。接種原株を氷上に置き、注射のためにビバリウムに移した。
C57BL/6雌マウスに、細胞接種前に識別チップ(BMDS IMI−1000 transponder)を移植した。対数増殖の際に採取したEL4−hBCMA細胞を各マウスの右側腹部に注射した(0.1mL中1.0×105細胞)。
マウスの目立った腫瘍成長を経過観察し、触知可能な腫瘍が見られた際に測定した。接種後11日目に、各マウスの腫瘍体積を記録した。マウスを、マッチング分布を用いたStudyLog Study Director Suite無作為化機能を用いて群に分けた。本試験では、0日目が無作為化および最初の処置の日であった。
腫瘍成長はFowler「ProMax」デジタルカリパスを用いて測定した。式(腫瘍体積=0.52×L×W2)を用いて腫瘍体積を求めるために腫瘍の長さと幅を測定した。腫瘍体積データをは、Studylog Study Director Suiteソフトウエアを用いて記録した。マウスで得られた個々のマウスの2,000mm3より大きい腫瘍測定値は試験から除き、安楽死させた。
本試験の目的は、EL4−hBCMAマウス同系腫瘍モデルにおいて、抗BMCA抗原結合タンパク質とICOSに対する作用物質を組み合わせた場合の抗腫瘍活性を評価することであった。平均腫瘍体積が150〜200mm3に達した際にマウスを下記の4群に無作為化した。
・IgG1/MMAF
・IgG1/GSK2857916
・ICOS/MMAF
・ICOS/GSK2857916
総ての統計分析はRソフトウエアを用いて行った。
図1は、7日目の平均腫瘍体積データを示す。図2は、最大83日間処置を受けた群の個々の腫瘍体積曲線を示す。同様の腫瘍成長阻害がGSK2857916単剤療法(IgG1/GSK2857916)およびICOSとGSK2857916の組合せ(ICOS/GSK2857916)でも見られた。試験83日目までに完全な腫瘍退縮が見られた。ICOS単剤療法では無腫瘍マウスは20%となり、GSK2857916では無腫瘍マウスは10%となった。ICOSとGSK2857916の組合せでは、無腫瘍マウスは30%となった。よって、この組合せは、ICOSまたはGSK2857916単独よりも10%〜20%生存に有利な傾向を示した。
Claims (20)
- それを必要とする対象において癌を治療する方法であって、抗BCMA抗原結合タンパク質とICOSに対する作用物質とを含んでなる治療上有効な用量の組合せを投与することを含んでなる、方法。
- それを必要とする対象において癌を治療する方法であって、抗BCMA抗原結合タンパク質と抗CD38抗原結合タンパク質とを含んでなる治療上有効な用量の組合せを投与することを含んでなる、方法。
- 前記抗BCMA抗原結合タンパク質が、配列番号1に示されるアミノ酸配列と少なくとも90%の配列同一性を有するアミノ酸配列を含んでなるCDRH1;配列番号2に示されるアミノ酸配列と少なくとも90%の配列同一性を有するアミノ酸配列を含んでなるCDRH2;配列番号3に示されるアミノ酸配列と少なくとも90%の配列同一性を有するアミノ酸配列を含んでなるCDRH3;配列番号4に示されるアミノ酸配列と少なくとも90%の配列同一性を有するアミノ酸配列を含んでなるCDRL1;配列番号5に示されるアミノ酸配列と少なくとも90%の配列同一性を有するアミノ酸配列を含んでなるCDRL2;および配列番号6に示されるアミノ酸配列と少なくとも90%の配列同一性を有するアミノ酸配列を含んでなるCDRL3を含んでなる、請求項1または請求項2に記載の方法。
- 前記抗BCMA抗原結合タンパク質が、配列番号7に示されるアミノ酸配列と少なくとも90%の配列同一性を有するアミノ酸配列を含んでなる重鎖可変領域(VH);および配列番号8に示されるアミノ酸配列と少なくとも90%の配列同一性を有するアミノ酸配列を含んでなる軽鎖可変領域(VL)を含んでなる抗体である、請求項1〜3のいずれか一項に記載の方法。
- 前記抗BCMA抗原結合タンパク質が、細胞毒素に結合された抗体を含んでなる免疫複合体である、請求項1〜4のいずれか一項に記載の方法。
- 前記細胞毒素がMMAEまたはMMAFから選択される、請求項5に記載の方法。
- 前記ICOSに対する作用物質が抗ICOS抗体である、請求項1および3〜5のいずれか一項に記載の方法。
- 前記抗ICOS抗体がICOSアゴニストである、請求項7に記載の方法。
- 前記抗ICOS抗体が配列番号13に示されるアミノ酸配列と少なくとも90%の配列同一性を有するアミノ酸配列を含んでなるCDRH1;配列番号14に示されるアミノ酸配列と少なくとも90%の配列同一性を有するアミノ酸配列を含んでなるCDRH2;配列番号15に示されるアミノ酸配列と少なくとも90%の配列同一性を有するアミノ酸配列を含んでなるCDRH3;配列番号16に示されるアミノ酸配列と少なくとも90%の配列同一性を有するアミノ酸配列を含んでなるCDRL1;配列番号17に示されるアミノ酸配列と少なくとも90%の配列同一性を有するアミノ酸配列を含んでなるCDRL2;および配列番号18に示されるアミノ酸配列と少なくとも90%の配列同一性を有するアミノ酸配列を含んでなるCDRL3を含んでなる、請求項7または8に記載の方法。
- 前記抗ICOS抗体が配列番号19に示されるアミノ酸配列と少なくとも90%同一のアミノ酸配列を含んでなるVHドメイン;および配列番号20に示されるアミノ酸配列と少なくとも90%同一のアミノ酸配列を含んでなるVLドメインを含んでなる、請求項7または8に記載の方法。
- 前記ICOSに対する作用物質が、S228P変異およびL235E変異を含んでなるFc領域を含んでなる、請求項1および3〜10のいずれか一項に記載の方法。
- 前記抗CD38抗原結合タンパク質が抗CD38抗体である、請求項2に記載の方法。
- 前記抗CD38抗体がダラツムマブである、請求項12に記載の方法。
- 前記癌が多発性骨髄腫、慢性リンパ球性白血病および非ホジキンリンパ腫から選択される、請求項1〜13のいずれか一項に記載の方法。
- 抗BCMA抗原結合タンパク質とICOSに対する作用物質とを含んでなる、癌の治療において使用するための組合せ。
- 抗BCMA抗原結合タンパク質と抗CD38抗原結合タンパク質とを含んでなる、癌の治療において使用するための組合せ。
- 癌の治療において使用するための医薬の製造における、抗BCMA抗原結合タンパク質とICOSに対する作用物質とを含んでなる組合せの使用。
- 癌の治療において使用するための医薬の製造における、抗BCMA抗原結合タンパク質と抗CD38抗原結合タンパク質とを含んでなる組合せの使用。
- (i)抗BCMA抗原結合タンパク質;
(ii)ICOSに対する作用物質と組み合わせた場合に癌の治療において使用するための説明書
を含んでなる、癌の治療において使用するためのキット。 - (i)抗BCMA抗原結合タンパク質;
(ii)抗CD38抗原結合タンパク質と組み合わせた場合に癌の治療において使用するための説明書
を含んでなる、癌の治療において使用するためのキット。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022173704A JP2023015171A (ja) | 2017-09-14 | 2022-10-28 | 癌の組合せ治療 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762558608P | 2017-09-14 | 2017-09-14 | |
US62/558,608 | 2017-09-14 | ||
PCT/IB2018/056969 WO2019053613A2 (en) | 2017-09-14 | 2018-09-12 | POLY THERAPY FOR THE TREATMENT OF CANCER |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022173704A Division JP2023015171A (ja) | 2017-09-14 | 2022-10-28 | 癌の組合せ治療 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020533380A true JP2020533380A (ja) | 2020-11-19 |
JP2020533380A5 JP2020533380A5 (ja) | 2021-10-21 |
Family
ID=63713946
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020515138A Pending JP2020533380A (ja) | 2017-09-14 | 2018-09-12 | 癌の組合せ治療 |
JP2022173704A Pending JP2023015171A (ja) | 2017-09-14 | 2022-10-28 | 癌の組合せ治療 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022173704A Pending JP2023015171A (ja) | 2017-09-14 | 2022-10-28 | 癌の組合せ治療 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20200255526A1 (ja) |
EP (1) | EP3692066A2 (ja) |
JP (2) | JP2020533380A (ja) |
CN (1) | CN111094353A (ja) |
BR (1) | BR112020005028A2 (ja) |
CA (1) | CA3075717A1 (ja) |
WO (1) | WO2019053613A2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL296039A (en) * | 2020-03-06 | 2022-10-01 | Aleta Biotherapeutics Inc | Preparations and methods for the treatment of cancer |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016120789A1 (en) * | 2015-01-28 | 2016-08-04 | Glaxosmithkline Intellectual Property Development Limited | Agonistic icos binding proteins |
WO2017093942A1 (en) * | 2015-12-01 | 2017-06-08 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
US8263746B2 (en) | 2004-02-06 | 2012-09-11 | Morphosys Ag | Anti-CD38 human antibodies and uses thereof |
US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
DK2860192T3 (en) | 2005-10-12 | 2018-01-02 | Morphosys Ag | Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 |
EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
KR20100017514A (ko) | 2007-05-07 | 2010-02-16 | 메디뮨 엘엘씨 | 항 icos 항체, 및 종양, 이식 및 자가면역성 질환 치료에서의 이의 용도 |
BRPI0921845A2 (pt) | 2008-11-12 | 2019-09-17 | Medimmune Llc | formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata |
CN101898945B (zh) | 2010-07-27 | 2013-05-08 | 大连理工大学 | 盐析萃取发酵液中丙酮和丁醇的方法 |
JP6220774B2 (ja) | 2011-03-31 | 2017-10-25 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Icosに対する抗体及びその使用 |
US20130101599A1 (en) * | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
PL3415531T3 (pl) | 2011-05-27 | 2024-02-26 | Glaxo Group Limited | Białka wiążące antygen |
TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
EP3689383A1 (en) | 2012-04-11 | 2020-08-05 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
EP2892928B1 (en) | 2012-09-03 | 2018-05-30 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies directed against icos for treating graft-versus-host disease |
EP2914628A1 (en) | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
US10077315B2 (en) | 2013-02-05 | 2018-09-18 | Engmab Sàrl | Bispecific antibodies against CD3 and BCMA |
AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
GB201317928D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
EP3131927B8 (en) | 2014-04-14 | 2020-12-23 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
JP6285274B2 (ja) | 2014-04-28 | 2018-02-28 | 株式会社ブリヂストン | バイアスタイヤ及びその製造方法 |
EP3172237A2 (en) | 2014-07-21 | 2017-05-31 | Novartis AG | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
AU2015292590B2 (en) | 2014-07-24 | 2020-01-16 | 2Seventy Bio, Inc. | BCMA chimeric antigen receptors |
EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
AU2015357533B2 (en) | 2014-12-05 | 2021-10-07 | Eureka Therapeutics, Inc. | Antibodies targeting B-cell maturation antigen and methods of use |
CN113698497A (zh) | 2014-12-05 | 2021-11-26 | 纪念斯隆-凯特琳癌症中心 | 靶向b-细胞成熟抗原的嵌合抗原受体及其用途 |
PL3273992T3 (pl) | 2015-03-23 | 2020-11-16 | Jounce Therapeutics, Inc. | Przeciwciała przeciwko icos |
DK3331910T3 (da) | 2015-08-03 | 2020-03-16 | Engmab Sarl | Monoklonale antistoffer mod humant b-cellemodningsantigen (bcma) |
EP3147954A1 (en) | 2015-09-22 | 2017-03-29 | Nokia Technologies Oy | Photodetector with conductive channel made from two dimensional material and its manufacturing method |
MX2019004621A (es) * | 2016-11-02 | 2019-11-28 | Engmab Sarl | Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple. |
-
2018
- 2018-09-12 WO PCT/IB2018/056969 patent/WO2019053613A2/en unknown
- 2018-09-12 EP EP18779782.4A patent/EP3692066A2/en active Pending
- 2018-09-12 BR BR112020005028-8A patent/BR112020005028A2/pt unknown
- 2018-09-12 JP JP2020515138A patent/JP2020533380A/ja active Pending
- 2018-09-12 US US16/646,921 patent/US20200255526A1/en not_active Abandoned
- 2018-09-12 CA CA3075717A patent/CA3075717A1/en active Pending
- 2018-09-12 CN CN201880060047.3A patent/CN111094353A/zh active Pending
-
2022
- 2022-08-26 US US17/822,705 patent/US20220411512A1/en active Pending
- 2022-10-28 JP JP2022173704A patent/JP2023015171A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016120789A1 (en) * | 2015-01-28 | 2016-08-04 | Glaxosmithkline Intellectual Property Development Limited | Agonistic icos binding proteins |
WO2017093942A1 (en) * | 2015-12-01 | 2017-06-08 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2019053613A3 (en) | 2019-05-16 |
CN111094353A (zh) | 2020-05-01 |
CA3075717A1 (en) | 2019-03-21 |
EP3692066A2 (en) | 2020-08-12 |
WO2019053613A2 (en) | 2019-03-21 |
US20200255526A1 (en) | 2020-08-13 |
JP2023015171A (ja) | 2023-01-31 |
US20220411512A1 (en) | 2022-12-29 |
BR112020005028A2 (pt) | 2020-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019228381B2 (en) | IL-15 variants and uses thereof | |
CN111727197A (zh) | 抗pd-1抗体和治疗方法 | |
ES2958587T3 (es) | Inhibidores de LRRC33 y uso de los mismos | |
CN110511278A (zh) | 抗b7-h6抗体、融合蛋白及其使用方法 | |
TWI793325B (zh) | 對cd3具特異性之抗體及其用途 | |
JP2022512642A (ja) | がんを治療するための抗MerTK抗体 | |
JP2021522847A (ja) | Ox40に対する完全ヒト抗体、それを調製する方法、およびその使用 | |
JP2020533382A (ja) | 癌の組合せ治療 | |
JP2020533383A (ja) | 癌の組合せ治療 | |
US20200181275A1 (en) | Combination therapy with icos agonist and ox40 agonist to treat cancer | |
US20220411512A1 (en) | Combination treatment for cancer | |
JP2024515879A (ja) | 抗siglec組成物及びその使用 | |
WO2023042202A1 (en) | Multispecific antibodies for use in treating diseases | |
TW202400232A (zh) | 多特異性分子與免疫檢查點抑制劑之組合 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210909 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210909 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220727 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220729 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230303 |